Home Cart Sign in  
Chemical Structure| 360575-28-6 Chemical Structure| 360575-28-6

Structure of 2-Bromo-6-fluorobenzaldehyde
CAS No.: 360575-28-6

Chemical Structure| 360575-28-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 360575-28-6 ]

CAS No. :360575-28-6
Formula : C7H4BrFO
M.W : 203.01
SMILES Code : O=CC1=C(F)C=CC=C1Br
MDL No. :MFCD03407341
InChI Key :PJNILWKRAKKEQM-UHFFFAOYSA-N
Pubchem ID :22473977

Safety of [ 360575-28-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 360575-28-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 39.49
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

17.07 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.61
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.18
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.82
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.63
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.08
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.47

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.85
Solubility 0.287 mg/ml ; 0.00141 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.17
Solubility 1.37 mg/ml ; 0.00673 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.48
Solubility 0.0668 mg/ml ; 0.000329 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.99 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.23

Application In Synthesis of [ 360575-28-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 360575-28-6 ]
  • Downstream synthetic route of [ 360575-28-6 ]

[ 360575-28-6 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 360575-28-6 ]
  • [ 2365-48-2 ]
  • [ 360575-29-7 ]
YieldReaction ConditionsOperation in experiment
89% With potassium carbonate In N,N-dimethyl-formamide at 60℃; for 15 h; General procedure: To a stirred solution of compound 1a-1n (9.90 mmol) in DMF (20 mL) were added methyl thioglycolate (10.9 mmol) and potassium carbonate (39.6 mmol). The resulting mixture was stirred at 60 °C for 15 h. The DMF was removed under reduced pressure,water (50 mL) was added and the mixture was extracted with ethylacetate (2 x 40 mL). The combined organic layers were dried withsodium sulfate, filtered, and the solvents were removed under reduced pressure to afford the title compound 2a-2n [31,34]. 4.1.1.1. Methyl 4-bromobenzo[b]thiophene-2-carboxylate (2a).Yield 89percent, white solid; m. p. 77-78 °C; 1H NMR (600 MHz,DMSO‑d6) δ 8.12 (d, J = 8.2 Hz, 1H), 8.01 (d, J = 0.6 Hz, 1H), 7.73 (d,J = 7.7 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 3.91 (s, 3H).
References: [1] European Journal of Medicinal Chemistry, 2019, p. 236 - 251.
[2] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 12, p. 2998 - 3001.
[3] Patent: US2003/166628, 2003, A1, .
[4] Patent: EP1724277, 2006, A1, . Location in patent: Page/Page column 28-29.
[5] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 9, p. 1010 - 1014.
 

Historical Records

Technical Information

• Alkyl Halide Occurrence • Arndt-Eistert Homologation • Barbier Coupling Reaction • Baylis-Hillman Reaction • Benzylic Oxidation • Birch Reduction • Blanc Chloromethylation • Bucherer-Bergs Reaction • Clemmensen Reduction • Complex Metal Hydride Reductions • Corey-Chaykovsky Reaction • Corey-Fuchs Reaction • Fischer Indole Synthesis • Friedel-Crafts Reaction • General Reactivity • Grignard Reaction • Hantzsch Dihydropyridine Synthesis • Henry Nitroaldol Reaction • Hiyama Cross-Coupling Reaction • Horner-Wadsworth-Emmons Reaction • Hunsdiecker-Borodin Reaction • Hydride Reductions • Hydrogenolysis of Benzyl Ether • Julia-Kocienski Olefination • Kinetics of Alkyl Halides • Knoevenagel Condensation • Kumada Cross-Coupling Reaction • Leuckart-Wallach Reaction • McMurry Coupling • Meerwein-Ponndorf-Verley Reduction • Mukaiyama Aldol Reaction • Nozaki-Hiyama-Kishi Reaction • Passerini Reaction • Paternò-Büchi Reaction • Petasis Reaction • Pictet-Spengler Tetrahydroisoquinoline Synthesis • Preparation of Aldehydes and Ketones • Preparation of Alkylbenzene • Preparation of Amines • Preparation of Carboxylic Acids • Prins Reaction • Reactions of Aldehydes and Ketones • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Reactions of Carboxylic Acids • Reactions of Dihalides • Reformatsky Reaction • Schlosser Modification of the Wittig Reaction • Schmidt Reaction • Specialized Acylation Reagents-Ketenes • Stetter Reaction • Stille Coupling • Stobbe Condensation • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling • Tebbe Olefination • Ugi Reaction • Vilsmeier-Haack Reaction • Wittig Reaction • Wolff-Kishner Reduction

Categories

Related Functional Groups of
[ 360575-28-6 ]

Fluorinated Building Blocks

Chemical Structure| 154650-16-5

A126591 [154650-16-5]

2-Bromo-6-fluoro-3-methylbenzaldehyde

Similarity: 0.98

Chemical Structure| 916792-21-7

A162806 [916792-21-7]

2-Bromo-5-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 497224-12-1

A493302 [497224-12-1]

5-Bromo-2-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 94569-84-3

A143953 [94569-84-3]

2-Bromo-5-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 59142-68-6

A235507 [59142-68-6]

2-Bromo-4-fluorobenzaldehyde

Similarity: 0.92

Aryls

Chemical Structure| 154650-16-5

A126591 [154650-16-5]

2-Bromo-6-fluoro-3-methylbenzaldehyde

Similarity: 0.98

Chemical Structure| 916792-21-7

A162806 [916792-21-7]

2-Bromo-5-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 497224-12-1

A493302 [497224-12-1]

5-Bromo-2-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 94569-84-3

A143953 [94569-84-3]

2-Bromo-5-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 59142-68-6

A235507 [59142-68-6]

2-Bromo-4-fluorobenzaldehyde

Similarity: 0.92

Bromides

Chemical Structure| 154650-16-5

A126591 [154650-16-5]

2-Bromo-6-fluoro-3-methylbenzaldehyde

Similarity: 0.98

Chemical Structure| 916792-21-7

A162806 [916792-21-7]

2-Bromo-5-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 497224-12-1

A493302 [497224-12-1]

5-Bromo-2-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 94569-84-3

A143953 [94569-84-3]

2-Bromo-5-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 59142-68-6

A235507 [59142-68-6]

2-Bromo-4-fluorobenzaldehyde

Similarity: 0.92

Aldehydes

Chemical Structure| 154650-16-5

A126591 [154650-16-5]

2-Bromo-6-fluoro-3-methylbenzaldehyde

Similarity: 0.98

Chemical Structure| 916792-21-7

A162806 [916792-21-7]

2-Bromo-5-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 497224-12-1

A493302 [497224-12-1]

5-Bromo-2-fluoro-4-methylbenzaldehyde

Similarity: 0.94

Chemical Structure| 94569-84-3

A143953 [94569-84-3]

2-Bromo-5-fluorobenzaldehyde

Similarity: 0.94

Chemical Structure| 59142-68-6

A235507 [59142-68-6]

2-Bromo-4-fluorobenzaldehyde

Similarity: 0.92